ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia

Mark A. Gregory, Angelo D'Alessandro, Francesca Alvarez-Calderon, Jihye Kim, Travis Nemkov, Biniam Adane, Andrii I. Rozhok, Amit Kumar, Vijay Kumar, Daniel A. Pollyea, Michael F. Wempe, Craig T. Jordan, Natalie J. Serkova, Aik-Choon Tan, Kirk C. Hansen, James DeGregori

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Activating mutations in FMS-like tyrosine kinase 3 (FLT3) are common in acute myeloid leukemia (AML) and drive leukemic cell growth and survival. Although FLT3 inhibitors have shown considerable promise for the treatment of AML, they ultimately fail to achieve long-term remissions as monotherapy. To identify genetic targets that can sensitize AML cells to killing by FLT3 inhibitors, we performed a genome-wide RNA interference (RNAi)-based screen that identified ATM (ataxia telangiectasia mutated) as being synthetic lethal with FLT3 inhibitor therapy.We found that inactivating ATM or its downstream effector glucose 6-phosphate dehydrogenase (G6PD) sensitizes AML cells to FLT3 inhibitor induced apoptosis. Examination of the cellular metabolome showed that FLT3 inhibition by itself causes profound alterations in central carbon metabolism, resulting in impaired production of the antioxidant factor glutathione, which was further impaired by ATM or G6PD inactivation. Moreover, FLT3 inhibition elicited severe mitochondrial oxidative stress that is causative in apoptosis and is exacerbated by ATM/G6PD inhibition. The use of an agent that intensifies mitochondrial oxidative stress in combination with a FLT3 inhibitor augmented elimination of AML cells in vitro and in vivo, revealing a therapeutic strategy for the improved treatment of FLT3 mutated AML.

Original languageEnglish
Pages (from-to)E6669-E6678
JournalProceedings of the National Academy of Sciences of the United States of America
Volume113
Issue number43
DOIs
Publication statusPublished - 2016 Oct 25
Externally publishedYes

Fingerprint

Ataxia Telangiectasia
Glucosephosphate Dehydrogenase
Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Oxidation-Reduction
Myeloid Cells
Oxidative Stress
Apoptosis
Metabolome
RNA Interference
Glutathione
Cell Survival
Carbon
Antioxidants
Genome
Mutation

Keywords

  • Acute myeloid leukemia
  • ATM
  • FLT3
  • Glutathione
  • Metabolism

ASJC Scopus subject areas

  • General

Cite this

ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. / Gregory, Mark A.; D'Alessandro, Angelo; Alvarez-Calderon, Francesca; Kim, Jihye; Nemkov, Travis; Adane, Biniam; Rozhok, Andrii I.; Kumar, Amit; Kumar, Vijay; Pollyea, Daniel A.; Wempe, Michael F.; Jordan, Craig T.; Serkova, Natalie J.; Tan, Aik-Choon; Hansen, Kirk C.; DeGregori, James.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 113, No. 43, 25.10.2016, p. E6669-E6678.

Research output: Contribution to journalArticle

Gregory, MA, D'Alessandro, A, Alvarez-Calderon, F, Kim, J, Nemkov, T, Adane, B, Rozhok, AI, Kumar, A, Kumar, V, Pollyea, DA, Wempe, MF, Jordan, CT, Serkova, NJ, Tan, A-C, Hansen, KC & DeGregori, J 2016, 'ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia', Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 43, pp. E6669-E6678. https://doi.org/10.1073/pnas.1603876113
Gregory, Mark A. ; D'Alessandro, Angelo ; Alvarez-Calderon, Francesca ; Kim, Jihye ; Nemkov, Travis ; Adane, Biniam ; Rozhok, Andrii I. ; Kumar, Amit ; Kumar, Vijay ; Pollyea, Daniel A. ; Wempe, Michael F. ; Jordan, Craig T. ; Serkova, Natalie J. ; Tan, Aik-Choon ; Hansen, Kirk C. ; DeGregori, James. / ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. In: Proceedings of the National Academy of Sciences of the United States of America. 2016 ; Vol. 113, No. 43. pp. E6669-E6678.
@article{63e9bcafbd274ebbaed5d13ca64800e3,
title = "ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia",
abstract = "Activating mutations in FMS-like tyrosine kinase 3 (FLT3) are common in acute myeloid leukemia (AML) and drive leukemic cell growth and survival. Although FLT3 inhibitors have shown considerable promise for the treatment of AML, they ultimately fail to achieve long-term remissions as monotherapy. To identify genetic targets that can sensitize AML cells to killing by FLT3 inhibitors, we performed a genome-wide RNA interference (RNAi)-based screen that identified ATM (ataxia telangiectasia mutated) as being synthetic lethal with FLT3 inhibitor therapy.We found that inactivating ATM or its downstream effector glucose 6-phosphate dehydrogenase (G6PD) sensitizes AML cells to FLT3 inhibitor induced apoptosis. Examination of the cellular metabolome showed that FLT3 inhibition by itself causes profound alterations in central carbon metabolism, resulting in impaired production of the antioxidant factor glutathione, which was further impaired by ATM or G6PD inactivation. Moreover, FLT3 inhibition elicited severe mitochondrial oxidative stress that is causative in apoptosis and is exacerbated by ATM/G6PD inhibition. The use of an agent that intensifies mitochondrial oxidative stress in combination with a FLT3 inhibitor augmented elimination of AML cells in vitro and in vivo, revealing a therapeutic strategy for the improved treatment of FLT3 mutated AML.",
keywords = "Acute myeloid leukemia, ATM, FLT3, Glutathione, Metabolism",
author = "Gregory, {Mark A.} and Angelo D'Alessandro and Francesca Alvarez-Calderon and Jihye Kim and Travis Nemkov and Biniam Adane and Rozhok, {Andrii I.} and Amit Kumar and Vijay Kumar and Pollyea, {Daniel A.} and Wempe, {Michael F.} and Jordan, {Craig T.} and Serkova, {Natalie J.} and Aik-Choon Tan and Hansen, {Kirk C.} and James DeGregori",
year = "2016",
month = "10",
day = "25",
doi = "10.1073/pnas.1603876113",
language = "English",
volume = "113",
pages = "E6669--E6678",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "43",

}

TY - JOUR

T1 - ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia

AU - Gregory, Mark A.

AU - D'Alessandro, Angelo

AU - Alvarez-Calderon, Francesca

AU - Kim, Jihye

AU - Nemkov, Travis

AU - Adane, Biniam

AU - Rozhok, Andrii I.

AU - Kumar, Amit

AU - Kumar, Vijay

AU - Pollyea, Daniel A.

AU - Wempe, Michael F.

AU - Jordan, Craig T.

AU - Serkova, Natalie J.

AU - Tan, Aik-Choon

AU - Hansen, Kirk C.

AU - DeGregori, James

PY - 2016/10/25

Y1 - 2016/10/25

N2 - Activating mutations in FMS-like tyrosine kinase 3 (FLT3) are common in acute myeloid leukemia (AML) and drive leukemic cell growth and survival. Although FLT3 inhibitors have shown considerable promise for the treatment of AML, they ultimately fail to achieve long-term remissions as monotherapy. To identify genetic targets that can sensitize AML cells to killing by FLT3 inhibitors, we performed a genome-wide RNA interference (RNAi)-based screen that identified ATM (ataxia telangiectasia mutated) as being synthetic lethal with FLT3 inhibitor therapy.We found that inactivating ATM or its downstream effector glucose 6-phosphate dehydrogenase (G6PD) sensitizes AML cells to FLT3 inhibitor induced apoptosis. Examination of the cellular metabolome showed that FLT3 inhibition by itself causes profound alterations in central carbon metabolism, resulting in impaired production of the antioxidant factor glutathione, which was further impaired by ATM or G6PD inactivation. Moreover, FLT3 inhibition elicited severe mitochondrial oxidative stress that is causative in apoptosis and is exacerbated by ATM/G6PD inhibition. The use of an agent that intensifies mitochondrial oxidative stress in combination with a FLT3 inhibitor augmented elimination of AML cells in vitro and in vivo, revealing a therapeutic strategy for the improved treatment of FLT3 mutated AML.

AB - Activating mutations in FMS-like tyrosine kinase 3 (FLT3) are common in acute myeloid leukemia (AML) and drive leukemic cell growth and survival. Although FLT3 inhibitors have shown considerable promise for the treatment of AML, they ultimately fail to achieve long-term remissions as monotherapy. To identify genetic targets that can sensitize AML cells to killing by FLT3 inhibitors, we performed a genome-wide RNA interference (RNAi)-based screen that identified ATM (ataxia telangiectasia mutated) as being synthetic lethal with FLT3 inhibitor therapy.We found that inactivating ATM or its downstream effector glucose 6-phosphate dehydrogenase (G6PD) sensitizes AML cells to FLT3 inhibitor induced apoptosis. Examination of the cellular metabolome showed that FLT3 inhibition by itself causes profound alterations in central carbon metabolism, resulting in impaired production of the antioxidant factor glutathione, which was further impaired by ATM or G6PD inactivation. Moreover, FLT3 inhibition elicited severe mitochondrial oxidative stress that is causative in apoptosis and is exacerbated by ATM/G6PD inhibition. The use of an agent that intensifies mitochondrial oxidative stress in combination with a FLT3 inhibitor augmented elimination of AML cells in vitro and in vivo, revealing a therapeutic strategy for the improved treatment of FLT3 mutated AML.

KW - Acute myeloid leukemia

KW - ATM

KW - FLT3

KW - Glutathione

KW - Metabolism

UR - http://www.scopus.com/inward/record.url?scp=84992315972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992315972&partnerID=8YFLogxK

U2 - 10.1073/pnas.1603876113

DO - 10.1073/pnas.1603876113

M3 - Article

C2 - 27791036

AN - SCOPUS:84992315972

VL - 113

SP - E6669-E6678

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 43

ER -